

Orbenin : oral penicillin for resistant staphylococci.

Contributors

Beecham Research Laboratories

Publication/Creation

Brentford : Beecham Research Laboratories, [1962?]

Persistent URL

<https://wellcomecollection.org/works/dybmb2vv>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

Orbenin

Orbenin
sodium cloxacillin REGD.

ORAL PENICILLIN FOR RESISTANT STAPHYLOCOCCI

Orbenin is chemically 3-*o*.chlorophenyl-5-methyl-4-isoxazolyl penicillin sodium salt monohydrate. It is a semi-synthetic penicillin derived from the penicillin nucleus 6-aminopenicillanic acid, isolated at the Beecham Research Laboratories in 1957.

Orbenin is stable to staphylococcal penicillinase and is highly active against not only resistant staphylococci, but also sensitive staphylococci and other Gram-positive organisms.

- ADVANTAGES**
- ★ Orbenin is stable to staphylococcal penicillinase, and highly effective against resistant staphylococci. Orbenin is four times more active than methicillin.
 - ★ Orbenin is also highly active against other Gram-positive organisms, including streptococci, pneumococci and sensitive staphylococci.
 - ★ Orbenin is bactericidal, acid-stable and well absorbed either by the oral or intramuscular routes.

INDICATIONS Orbenin is indicated for immediate use in the treatment of infections caused by resistant staphylococci or, in the absence of a sensitivity report, for suspected resistant staphylococcal infections, e.g. pneumonias, septicaemia, post-operative wound infections.

Being highly active against other Gram-positive organisms Orbenin is of particular value in treating mixed Gram-positive infections e.g. infected burns, where resistant staphylococci may be present.



A PRODUCT OF BRITISH RESEARCH

ORAL PENICILLIN
FOR RESISTANT
STAPHYLOCOCCI

Orbenin

sodium cloxacillin

REGD.

**ADMINISTRATION
AND
DOSAGE**

Adults:

Oral
500 mg. 6-hourly.

Orbenin should be taken one hour before meals in order to obtain optimum serum levels.

Intramuscular
250 mg. 4-6 hourly.

Contents of each 250 mg. vial should be dissolved in 1.5 ml. "Water for Injection" B.P.

Children:

0-2 years - Quarter adult dose.
3-10 years - Half adult dose.

**CONTRA-
INDICATIONS**

Orbenin should not be given to patients with a penicillin allergy. Orbenin is not suitable for ophthalmic use.

AVAILABILITY

Capsules: dual coloured black/orange, containing 250 mg. cloxacillin as the sodium salt, packed in canisters of 50 and 250.

Vials: containing 250 mg. cloxacillin as the sodium salt, packed in cartons of 5, 25 and 100.

PRICE —Basic N.H.S. Capsules: 50's 87/-; 250's, 414/-.
Vials: 7/2 each.

REFERENCES

1. Nayler, J. H. C., *et al*, *Nature*, (1962), 195, 1264.
2. Knudsen, E. T. *et al*, *Lancet*, (1962), ii, 632.
3. Stewart, G. T., *et al*, *Lancet*, (1962) ii, 634.
4. Lowbury, E. J. L. and Miller, R. W. S., *Lancet*, (1962), ii, 640.
5. Editorial, *Lancet*, (1962), ii, 851.
6. Knox, R., *et al*, *Brit. med. J.*, (1962), ii, 831.
7. Smith, J. T., *et al*, *Nature*, (1962), 195, 1300.



ORBENIN is a product of British research at

BEECHAM RESEARCH LABORATORIES LIMITED

Brentford, England Telephone: ISLeworth 4111

9852/11/62